Keiko Yanagihara^1,*, Masato Yoshida², Kensaku Awaji², Tamami Yamakawa¹, Sena Kato¹, Miki Tamura¹, Koji Nagata³

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.073891 - 30 December 2025

Abstract Background: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have transformed the management of hormone receptor–positive/HER2–negative (HR+/HER2–) advanced breast cancer, yet evidence for elderly or poor-performance patients remains limited. This study examined real-world outcomes of palbociclib plus endocrine therapy in Asian patients, with additional subgroup analyses by age and performance status. Methods: We retrospectively analyzed 46 consecutive Asian patients with recurrent or de novo HR+/HER2− breast cancer treated with first-line palbociclib plus ET between April 2021 and March 2025. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall response rate (ORR), disease control rate (DCR), and safety.… More >

LING MA^1,#, ZIRUI JIANG^1,#, XIAO HOU¹, YUTING XU¹, ZIYUN CHEN¹, SIYI ZHANG¹, HANXUE LI¹, SHAOJIE MA¹, GENG ZHANG², XIUJUN WANG^1,*, JING JI^1,*

BIOCELL, Vol.48, No.5, pp. 847-860, 2024, DOI:10.32604/biocell.2024.050868 - 06 May 2024

Abstract Background: Regulatory proteins involved in human cellular division and proliferation, cyclin-dependent kinases 4 and 6 (CDK4/6) are overexpressed in numerous cancers, including triple-negative breast cancer (TNBC). TNBC is a common pathological subtype of breast cancer that is prone to recurrence and metastasis, and has a single treatment method. As one of the CDK4/6 inhibitors, abemaciclib can effectively inhibit the growth of breast tumors. In this study, we synthesized LA-D-B1, a derivative of Abemaciclib, and investigated its anti-tumor effects in breast cancer. Methods: Cellular viability was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cell cloning and… More >

JIYU WANG^1,#, LIUYING YI^2,#, KEKE HUANG¹, YANGYANG WANG¹, HUIPING WANG¹, ZHIMIN ZHAI^1,*

BIOCELL, Vol.48, No.3, pp. 453-462, 2024, DOI:10.32604/biocell.2024.047871 - 15 March 2024

Abstract Background: The primary cause of treatment failure in patients with refractory or relapsed B-cell non-Hodgkin lymphoma (r/r B-NHL) is resistance to current therapies, and therapy-induced senescence (TIS) stands out as a crucial mechanism contributing to tumor drug resistance. Here, we analyzed SENEX/Rho GTPase Activating Protein 18 (ARHGAP18) expression and prognostic significance in doxorubicin-induced B-NHL-TIS model and r/r B-NHL patients, investigating its target in B-NHL cell senescence and the effect of combining specific inhibitors on apoptosis resistance in B-NHL-TIS cells. Methods: Raji cells were transfected with the human SENEX shRNA recombinant lentiviral vector (Sh-SENEX) and the empty vector… More >